Canaccord Genuity downgrades Stryker to Hold from Buy, lowers price target to $300 from $385

What happened

Canaccord Genuity downgraded Stryker to Hold from Buy and lowered its price target to $300 from $385, a 22.1% decrease. The new target implies a 3.8% downside from Stryker's October 29 close of $311.75.

Confirmed

Global impact / market context

A downgrade to Hold means the broker no longer expects strong gains and now sees the stock as fairly valued. The lower $300 target signals reduced expectations for future profit or growth, which can push some investors to sell or hold off buying shares.

Analyst inference

Other analysts remain more positive: Citizens, Evercore ISI Group and Needham keep Buy or Outperform ratings, with targets from $304 to $390. That split shows disagreement about Stryker's outlook, so the stock may react to differing views rather than one clear consensus.

Analyst inference

What to watch

1. The five most recent analyst notes over the past 30 days show price targets ranging from $304 to $390, so watch whether other firms follow Canaccord and lower their targets. Confirmed
2. Watch whether Canaccord explains the reasons behind the downgrade, such as slower revenue growth or pressure on profit per sale, which means the money kept from each sale. Proposed
3. Track Stryker's upcoming results for signs of weaker sales or higher costs; if they confirm the cautious view, more analysts could cut ratings and targets. Analyst inference

Evidence

• Original source link unavailable